Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 1;36(6):1105-1115.
doi: 10.1681/ASN.0000000602. Epub 2025 Jan 16.

Biomarker Panels for Discriminating Risk of CKD Progression in Children

Jason H Greenberg  1   2 , Alison G Abraham  3 , Yunwen Xu  4 , Jeffrey R Schelling  5 , Steven G Coca  6 , Sarah J Schrauben  7 , F Perry Wilson  2 , Sushrut S Waikar  8 , Ramachandran S Vasan  9 , Orlando M Gutiérrez  10 , Michael G Shlipak  11 , Joachim H Ix  12 , Bradley A Warady  13 , Paul L Kimmel  14 , Joseph V Bonventre  15 , Chirag R Parikh  16 , Michelle Denburg  17 , Susan Furth  1 ; CKD Biomarkers Consortium
Collaborators, Affiliations

Biomarker Panels for Discriminating Risk of CKD Progression in Children

Jason H Greenberg et al. J Am Soc Nephrol. .

Abstract

Key Points:

  1. Plasma biomarkers (kidney injury molecule-1, KIM-1), urine biomarkers (EGF/creatinine and urine albumin-creatinine ratio), and eGFR identified four prognostic groups in children with CKD progression.

  2. A panel of biomarkers may better capture the complexity of kidney disease in children and may allow for a broader assessment of kidney health.

Background: We have previously studied biomarkers of tubular health (EGF), injury (kidney injury molecule-1 [KIM-1]), dysfunction (α-1 microglobulin), and inflammation (TNF receptor-1, TNF receptor-2, monocyte chemoattractant protein-1, YKL-40, and soluble urokinase plasminogen activator receptor) and demonstrated that plasma KIM-1, TNF receptor-1, TNF receptor-2, urine KIM-1, EGF, monocyte chemoattractant protein-1, and urine α-1 microglobulin are each independently associated with CKD progression in children. In this study, we used bootstrapped survival trees to identify a combination of biomarkers to predict CKD progression in children.

Methods: The Chronic Kidney Disease in Children (CKiD) Cohort Study prospectively enrolled children aged 6 months to 16 years with an eGFR of 30–90 ml/min per 1.73 m2. We measured biomarkers in stored plasma and urine collected 5 months after study enrollment. The primary outcome of CKD progression was a composite of 50% eGFR decline or kidney failure. We constructed a regression tree–based model for predicting the time to the composite event, using a panel of clinically relevant biomarkers with empirically derived thresholds, in addition to conventional risk factors.

Results: Of the 599 children included, the median age was 12 years (interquartile range [IQR], 8–15), 371 (62%) were male, baseline urine protein-creatinine ratio was 0.33 (IQR, 0.12–0.95) mg/mg, and baseline eGFR was 53 (IQR, 40–66) ml/min per 1.73 m2. Overall, 205 children (34%) reached the primary outcome of CKD progression. A single regression tree–based model using the most informative predictors with data-driven biomarker thresholds suggested a final set of four prognosis groups. In the final model, urine albumin/creatinine was the variable with the highest importance and along with urine EGF/creatinine identified the highest risk group of 24 children, 100% of whom developed CKD progression at a median time of 1.3 years (95% confidence interval [CI], 1.0 to 1.7). When the regression tree–derived risk group classifications were added to prediction models including the clinical risk factors, the C-statistic increased from 0.76 (95% CI, 0.71 to 0.80) to 0.85 (95% CI, 0.81 to 0.88).

Conclusions: Using regression tree–based methods, we identified a biomarker panel of urine albumin/creatinine, urine EGF/creatinine, plasma KIM-1, and eGFR, which significantly improved discrimination for CKD progression.

Keywords: CKD; children; chronic GN; pediatric nephrology; progression of renal failure; proteinuria; risk factors.

PubMed Disclaimer

Conflict of interest statement

Disclosure forms, as provided by each author, are available with the online version of the article at http://links.lww.com/JSN/F31.

References

    1. McDonald SP, Craig JC.; Australian and New Zealand Paediatric Nephrology Association. Long-term survival of children with end-stage renal disease. New Engl J Med. 2004;350(26):2654–2662. doi:10.1056/NEJMoa031643 - DOI - PubMed
    1. Mendley SR Matheson MB Shinnar S, et al. . Duration of chronic kidney disease reduces attention and executive function in pediatric patients. Kidney Int. 2015;87(4):800–806. doi:10.1038/ki.2014.323 - DOI - PMC - PubMed
    1. Harambat J Bonthuis M van Stralen KJ, et al. . Adult height in patients with advanced CKD requiring renal replacement therapy during childhood. Clin J Am Soc Nephrol. 2014;9(1):92–99. doi:10.2215/CJN.00890113 - DOI - PMC - PubMed
    1. Warady BA Abraham AG Schwartz GJ, et al. . Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the chronic kidney disease in children (CKiD) cohort. Am J Kidney Dis. 2015;65(6):878–888. doi:10.1053/j.ajkd.2015.01.008 - DOI - PMC - PubMed
    1. Wong CJ, Moxey-Mims M, Jerry-Fluker J, Warady BA, Furth SL. CKiD (CKD in children) prospective cohort study: a review of current findings. Am J Kidney Dis. 2012;60(6):1002–1011. doi:10.1053/j.ajkd.2012.07.018 - DOI - PMC - PubMed

LinkOut - more resources